Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Myeloid 5Other hematologic neoplasm 2

Conditions

Thrombocythemia, Essential 3Polycythemia Vera 3Primary Myelofibrosis 2Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Extensive Stage Lung Small Cell Carcinoma 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × bomedemstat × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05597306 2026-01-08

VenBom

University of Miami

Phase 1 Recruiting
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04262141 2026-01-07

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

University of Miami

Phase 2 Active not recruiting
4 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT05223920 2025-09-22

MK-3543-005

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
81 enrolled 13 charts
Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

NCT05191797 2024-09-26

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

University of Washington

Phase 1/2 Terminated
3 enrolled 8 charts

Extensive Stage Lung Small Cell Carcinoma

NCT02842827 2023-07-11

IMG-7289-CTP-101

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 1/2 Completed
45 enrolled 41 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡